keyword
https://read.qxmd.com/read/38058118/prognostic-factors-for-uterine-sarcoma-and-carcinosarcoma-insights-from-a-10-year-follow-up-study
#21
JOURNAL ARTICLE
Beata Kotowicz, Anna Dańska-Bidzińska, Małgorzata Fuksiewicz, Anna Nasierowska-Guttmejer, Dorota Raczkiewicz, Mariusz Gujski, Szymon Piątek, Mariusz Bidziński
BACKGROUND Uterine sarcomas and carcinomas are rare tumors and treatment outcomes are far from expected. We investigated the prognostic significance of selected serum biomarkers and the impact of some clinical and tissue factors on overall survival (OS) at 10-year follow-up. MATERIAL AND METHODS The material for analysis was a group of 34 patients with uterine sarcomas and 18 with carcinomas. Immunohistochemistry was performed to determine Ki 67, p53 and ER and PR. Concentrations: CA 125, IL8, VEGF, SFTL1, VEGF R2, sTNFRI and MMP-9 were determined in the serum of patients before treatment and in the control group...
December 7, 2023: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://read.qxmd.com/read/38046506/clinical-profile-and-treatment-outcomes-of-malignant-mixed-mullerian-tumors-of-the-uterus-a-single-center-experience
#22
JOURNAL ARTICLE
Niranjan Vijayaraghavan, Dinesh Ravikumar
Background A malignant mixed Mullerian tumor (MMMT), otherwise known as carcinosarcoma, is a rare and aggressive malignancy involving the uterus. Despite aggressive treatment, they have poor outcomes. We performed this study to analyze the clinical profile, prognostic features, and treatment outcomes of patients treated for MMMT of the uterine corpus in our center. Methodology A study sample from a database of patients treated at a tertiary care center in South India between January 2015 and December 2019 was analyzed retrospectively...
October 2023: Curēus
https://read.qxmd.com/read/38029652/molecular-landscape-of-erbb2-her2-gene-amplification-among-patients-with-gynecologic-malignancies-clinical-implications-and-future-directions
#23
JOURNAL ARTICLE
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L Giuntoli, Sarah H Kim, Fiona Simpkins, Lainie Martin, Emily M Ko
OBJECTIVE: Investigate the prevalence of ERBB2/HER2 gene amplification among patients with gynecologic malignancies. METHODS: The American Association of Cancer Research (AACR) Genomics Evidence of Neoplasia Information Exchange (GENIE) (version 13.1) database was accessed and patients with endometrial, ovarian, and cervical cancer were identified. Patients with available data on the presence of copy-number gene alterations were selected for further analysis. Incidence of ERBB2 amplification following stratification by tumor site and histology was evaluated...
November 28, 2023: Gynecologic Oncology
https://read.qxmd.com/read/38007705/apobec3c-is-a-novel-target-for-the-immune-treatment-of-lower-grade-gliomas
#24
JOURNAL ARTICLE
Shufa Zhao, Yuntao Li, Jie Xu, Liang Shen
BACKGROUND: Apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) type 3C (A3C) has been identified as a cancer molecular biomarker in the past decade. However, the practical role of A3C in lower-grade gliomas (LGGs) in improving the clinical outcome remains unclear. This study aims to discuss the function of A3C in immunotherapy in LGGs. METHODS: The RNA-Sequencing (RNA-seq) and corresponding clinical data were extracted from UCSC Xena and the results were verified in the Chinese Glioma Genome Atlas (CGGA)...
November 26, 2023: Neurological Research
https://read.qxmd.com/read/37970762/ultrasound-features-using-musa-terms-and-definitions-in-uterine-sarcoma-and-leiomyoma-retrospective-cohort-study
#25
JOURNAL ARTICLE
C De Bruyn, J Ceusters, K Vanden Brande, S Timmerman, W Froyman, D Timmerman, A-S Van Rompuy, A Coosemans, T Van den Bosch
OBJECTIVE: A timely and correct preoperative diagnosis of a uterine sarcoma will increase patients' survival. The primary aim of our study was to describe the ultrasound features in uterine sarcomas compared to uterine leiomyomas based on MUSA (Morphological Uterus Sonographic Assessment) terms and definitions. The secondary aim was to assess the interobserver agreement of the MUSA ultrasound features. METHODS: This retrospective cohort study assessed uterine sarcomas from 1997 until 2019 and uterine leiomyomas from 2016 until 2019 treated in a single tertiary center...
November 16, 2023: Ultrasound in Obstetrics & Gynecology
https://read.qxmd.com/read/37914528/mesothelin-expression-in-gynecologic-carcinosarcoma-clinicopathological-significance-and-correlation-with-her2-expression
#26
JOURNAL ARTICLE
Rui Kitadai, Tadaaki Nishikawa, Hiroshi Yoshida, Chiharu Mizoguchi, Kasumi Yamamoto, Tomoyasu Kato, Kan Yonemori
OBJECTIVE: This study aimed to evaluate mesothelin (MSLN) expression and determine its clinical significance and correlation with human epidermal growth factor receptor 2 (HER2) expression in gynecological carcinosarcoma. METHODS: We retrospectively evaluated patients with uterine carcinosarcoma (UCS) and ovarian carcinosarcoma (OCS) who underwent surgery between 1997 and 2019. Immunohistochemical staining of formalin-fixed, paraffin-embedded specimens for MSLN (clone SP74) and HER2 (clone 4A5) was also performed...
October 12, 2023: Journal of Gynecologic Oncology
https://read.qxmd.com/read/37835384/racial-and-ethnic-disparities-in-gynecologic-carcinosarcoma-a-single-institution-experience
#27
JOURNAL ARTICLE
Kristina E Mercado, Nora M Badiner, Canty Wang, Laura Denham, Juli J Unternaehrer, Linda J Hong, Yevgeniya J Ioffe
We aimed to determine the incidence, treatment regimen, and treatment outcomes (including progression-free survival and overall survival) of gynecologic carcinosarcoma, a rare, aggressive, and understudied gynecologic malignancy. This retrospective review included all patients with gynecologic cancers diagnosed and treated at a single tertiary care comprehensive cancer center between January 2012 and May 2021. A total of 2116 patients were eligible for review, of which 84 cases were identified as carcinosarcoma: 66 were uterine (5...
September 23, 2023: Cancers
https://read.qxmd.com/read/37795251/fatal-pulmonary-thromboembolism-associated-with-uterine-carcinosarcoma
#28
JOURNAL ARTICLE
Giorgia Lodetti, Stefano Tambuzzi, Salvatore Andreola, Guendalina Gentile, Riccardo Zoja
No abstract text is available yet for this article.
2023: Autopsy & Case Reports
https://read.qxmd.com/read/37785689/single-institution-experience-of-the-effect-of-adjuvant-radiation-on-outcomes-for-patients-with-uterine-carcinosarcoma
#29
JOURNAL ARTICLE
R Tobillo, H Grace, K Sykes Martin, N Ali, A B Patel Jr, P R Patel, J W Shelton, J S Remick, T Y Eng
PURPOSE/OBJECTIVE(S): Uterine carcinosarcoma (UCS) is a rare but aggressive malignancy with poor outcomes. Due to its low incidence, there is no well-established optimal treatment. Standard treatment involves surgery and chemotherapy (CT) +/- adjuvant radiation therapy (RT). Our primary aim was to determine if patients who underwent adjuvant RT had improved distant metastasis free survival (DMFS) and locoregional recurrence free survival (LRRFS). Our secondary aim was to determine the effect of adjuvant RT on overall survival (OS)...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37785677/single-institute-experience-treating-uterine-carcinosarcoma-outcome-analysis
#30
JOURNAL ARTICLE
V R Sim, M Gupta, B Taylor, V Mullassery, A Winship, K Chan, J Galante, I White
PURPOSE/OBJECTIVE(S): Uterine carcinosarcoma (UCS) is rare with a poor prognosis. We report over 10 years' experience, reporting prognostic and predictive factors for overall survival (OS) and disease-free survival (DFS). MATERIALS/METHODS: Patient, tumor, treatment and relapse characteristics of 168 women with stages I-IVB UCS treated at our institute between 2010 and 2020 were analyzed. OS and DFS at 2 and 5 years were the primary outcomes, estimated with Kaplan-Meier...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37770766/h3k27me3-deficiency-in-dedifferentiated-carcinoma-and-carcinosarcoma-of-the-endometrium
#31
JOURNAL ARTICLE
Atsushi Kihara, Yusuke Amano, Noriyoshi Fukushima, Hiroyuki Fujiwara, Toshiro Niki
The present study immunohistochemically investigated trimethylation of lysine 27 of histone 3 (H3K27me3) expression in 769 endometrial carcinomas and 196 uterine mesenchymal tumors. One dedifferentiated endometrial carcinoma (DEC) and one carcinosarcoma showed H3K27me3 deficiency that was limited to undifferentiated and sarcomatous components, respectively. Switch/sucrose nonfermenting (SWI/SNF) complex subunits (SMARCA4, SMARCB1, and ARID1A/1B) and mismatch repair proteins were proficient in both tumors. The dimethylation of H3K27 (H3K27me2) was deficient in the undifferentiated component, whereas the sarcomatous component had scattered H3K27me2-positive cells...
September 28, 2023: Virchows Archiv: An International Journal of Pathology
https://read.qxmd.com/read/37749866/in-vivo-intra-uterine-delivery-of-tat-fused-cre-recombinase-and-crispr-cas9-editing-system-in-mice-unveil-histopathology-of-pten-p53-deficient-endometrial-cancers
#32
JOURNAL ARTICLE
Raúl Navaridas, Maria Vidal-Sabanés, Anna Ruiz-Mitjana, Gisela Altés, Aida Perramon-Güell, Andree Yeramian, Joaquim Egea, Mario Encinas, Sonia Gatius, Xavier Matias-Guiu, Xavier Dolcet
Phosphatase and TENsin homolog (Pten) and p53 are two of the most frequently mutated tumor suppressor genes in endometrial cancer. However, the functional consequences and histopathological manifestation of concomitant p53 and Pten loss of function alterations in the development of endometrial cancer is still controversial. Here, it is demonstrated that simultaneous Pten and p53 deletion is sufficient to cause epithelial to mesenchymal transition phenotype in endometrial organoids. By a novel intravaginal delivery method using HIV1 trans-activator of transcription cell penetrating peptide fused with a Cre recombinase protein (TAT-Cre), local ablation of both p53 and Pten is achieved specifically in the uterus...
September 25, 2023: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/37729375/the-prognostic-significance-of-the-heterologous-component-in-uterine-carcinosarcomas
#33
JOURNAL ARTICLE
Behzat Can, Volkan Karataşli, İlker Çakir, Sevil Sayhan, Kemal Hansu, Oğuzhan Kuru
OBJECTIVE: Uterine carcinosarcomas are aggressive, rare biphasic tumors with malignant epithelial and malignant sarcomatous components. The prognostic significance of the presence of extrauterine sarcoma (heterologous component) is controversial. Therefore, the aim of this study was to investigate the effect of heterologous components in uterine carcinosarcomas on disease-free survival, overall survival, and other prognostic factors. METHODS: Clinical and histopathological data from patients treated for uterine carcinosarcoma in a tertiary cancer center in Turkey between July 2000 and January 2020 were collected...
2023: Revista da Associação Médica Brasileira
https://read.qxmd.com/read/37679206/gynecological-carcinosarcomas-overview-and-future-perspectives
#34
JOURNAL ARTICLE
Laetitia Collet, Andrea María González López, Clémence Romeo, Pierre Méeus, Nicolas Chopin, Léa Rossi, Elise Rowinski, Anne-Agathe Serre, Corrinne Rannou, Adrien Buisson, Isabelle Treilleux, Isabelle Ray-Coquard
Gynecologic carcinosarcoma (CS) are rare and aggressive tumors composed of high-grade carcinoma and sarcoma. Carcinosarcoma account for less than 5% of uterine and ovarian carcinoma and patients have poor outcome with a 5-year overall survival of less than 30%. In early-stage setting, the treatment mainstay is surgery and adjuvant chemoradiotherapy or adjuvant chemotherapy in uterine (UCS) and ovarian CS (OCS), respectively. In metastatic or advanced stage disease, chemotherapy is the rule with a lower response rate and poorer prognosis compared to other high-grade carcinomas...
September 5, 2023: Bulletin du Cancer
https://read.qxmd.com/read/37627113/her2-oncogene-as-molecular-target-in-uterine-serous-carcinoma-and-uterine-carcinosarcoma
#35
REVIEW
Blair McNamara, Levent Mutlu, Michelle Greenman, Justin Harold, Alessandro Santin
Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) are two rare histologic variants of uterine carcinoma, with distinct molecular profiles and aggressive metastatic potential. As the effectivity of traditional platinum-based chemotherapy for USC and UCS is low, and there are high rates of resistance and recurrence, the development of novel targeted therapeutics is needed. Human epidermal growth factor receptor 2 (HER2) has proven to be an oncogene of increasing interest in these cancers, as HER2 protein overexpression and/or c- ERBB2 gene amplification ranges from ~30 to 35% in USC, and between ~15 and 20% in UCS...
August 14, 2023: Cancers
https://read.qxmd.com/read/37623209/characteristic-of-endometrial-stromal-sarcoma-by-algorithm-of-potential-biomarkers-for-uterine-mesenchymal-tumor
#36
Takuma Hayashi, Kenji Sano, Nobuo Yaegashi, Kaoru Abiko, Ikuo Konishi
The benign tumor uterine leiomyoma (UL) develops from the smooth muscle tissue that constitutes the uterus, whereas malignant tumor uterine sarcoma develops from either the smooth muscle tissue or stroma and is different from UL and endometrial cancer. Uterine sarcoma is broadly classified into three types: uterine leiomyosarcoma, endometrial stromal sarcoma (ESS), and carcinosarcoma. Although uterine leiomyosarcoma and ESS are both classified as uterine sarcoma, they significantly differ in terms of their sites of occurrence, symptoms, and treatment methods...
July 25, 2023: Current Issues in Molecular Biology
https://read.qxmd.com/read/37593813/figo-staging-of-endometrial-cancer-2023
#37
JOURNAL ARTICLE
Jonathan S Berek, Xavier Matias-Guiu, Carien Creutzberg, Christina Fotopoulou, David Gaffney, Sean Kehoe, Kristina Lindemann, David Mutch, Nicole Concin
INTRODUCTION: Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes...
September 2023: Journal of Gynecologic Oncology
https://read.qxmd.com/read/37530323/clinicopathological-and-molecular-analyses-of-uterine-carcinosarcomas-using-next-generation-sequencing-a-single-center-experience
#38
JOURNAL ARTICLE
Ezgi Genc Erdogan, Tülin D Yalta, Nuray Can, Necdet Süt, Ebru Taştekin, Ufuk Usta, Fulya Öz Puyan, Fatma E Usturalı Keskin, Busem B Kurt
BACKGROUND: Uterine carcinosarcomas (UCS) constitute 3-4% of all uterine malignancies and 16% of deaths caused due to uterine neoplasms. AIM: In this study, we aimed to perform DNA-based mutation analysis in 12 genes (KRAS, NRAS, EGFR, C-KIT, BRAF, PDGFRA, ALK, ERBB2, ERBB3, ESR1, RAF1, PIK3CA) to determine the molecular subtypes of UCS using next-generation sequencing (NGS) in patients with aggressive UCS and poor prognosis. We aimed to compare the results of our analysis with clinicopathological data to contribute to the development of targeted therapy approaches related to the molecular changes of UCS...
2023: Indian Journal of Pathology & Microbiology
https://read.qxmd.com/read/37506533/folate-receptor-alpha-is-widely-expressed-and-a-potential-therapeutic-target-in-uterine-and-ovarian-carcinosarcoma
#39
JOURNAL ARTICLE
Ayumi Saito, Tadaaki Nishikawa, Hiroshi Yoshida, Chiharu Mizoguchi, Rui Kitadai, Kasumi Yamamoto, Shu Yazaki, Yuki Kojima, Mitsuya Ishikawa, Tomoyasu Kato, Kan Yonemori
OBJECTIVE: Folate receptor alpha (FRα), which is expressed in various cancers, is a potential therapeutic target. However, its expression and clinical significance in uterine (UCS) and ovarian carcinosarcoma (OCS) remain to be elucidated. METHODS: This retrospective study included patients with gynecologic carcinosarcoma who underwent primary surgery between 1997 and 2019 at our institution. Immunohistochemical staining of surgical FFPE specimens was performed for FRα and HER2...
September 2023: Gynecologic Oncology
https://read.qxmd.com/read/37417301/prognostic-significance-of-heterologous-component-in-carcinosarcoma-of-the-gynecologic-organs-a-systematic-review-and-meta-analysis
#40
JOURNAL ARTICLE
Younghoon Kim, Gyeong Hoon Kang, Haeryoung Kim
OBJECTIVE: The aim of this study is to determine the histologic presence of heterologous component as a prognostic factor in gynecologic carcinosarcoma through a systematic review and meta-analysis. METHODS: PubMed, Web of Science, and Embase were searched for publications. Studies that evaluated survival effect of sarcomatous component based on histology in human ovarian or uterine carcinosarcoma were included. Two authors independently reviewed the references based on eligibility criteria and extracted the data including primary tumor site, survival outcome, type of survival outcome, and proportion of each sarcomatous differentiation...
June 26, 2023: Journal of Gynecologic Oncology
keyword
keyword
46612
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.